

## DAFTAR PUSTAKA

1. Rujito L, Sasongko TH. Genetic Background of  $\beta$  Thalassemia Modifier: Recent Update. *J Biomed Transl Res*. 2018;4(1):12.
2. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. *Bull World Health Organ*. 2008;86(6):480–7.
3. Hernanda PY, Tursilowati L, Arkesteijn SGJ, Ugrasena IDG, Larasati MCS, Soeatmadji SM, et al. Towards a prevention program for  $\beta$ -thalassemia. the molecular spectrum in East Java, Indonesia. *Hemoglobin*. 2012;36(1):1–6.
4. Rujito L, Basalamah M, Mulatsih S, Sofro ASM, Rujito L, Basalamah M, et al. Molecular Scanning of  $\beta$  -Thalassemia in the Southern Region of Central Java , Indonesia ; a Step Towards a Local Prevention Program Molecular Scanning of  $\beta$  -Thalassemia in the Southern Region of Central Java , Indonesia ; a Step Towards a Local Prevention. 2015;0269(October).
5. Maskoen AM, Rahayu NS, Reniarti L, Susanah S, Laksono B, Fauziah PN, et al. Mutation spectrum of  $\beta$ -globin gene in thalassemia patients at Hasan Sadikin Hospital - West Java Indonesia. *Cell Mol Biol*. 2017;63(12):22–4.
6. Rawa K, Szczesny RJ, Owczarek EP, Adamowicz-Salach A, Klukowska A, Demkow U, et al. Two novel C-terminal frameshift mutations in the  $\beta$ -globin gene lead to rapid mRNA decay. *BMC Med Genet*. 2017;18(1):1–6.
7. Porter J. Beyond transfusion therapy: New therapies in thalassemia including drugs, alternate donor transplant, and gene therapy. *Hematol (United States)*. 2018;2018(1):361–70.
8. Gnanapragasam MN, Crispino JD, Ali AM, Weinberg R, Hoffman R, Raza A, et al. Survey and evaluation of mutations in the human KLF1 transcription unit. *Sci Rep*. 2018;8(1):1–8.
9. Amjad F, Fatima T, Fayyaz T, Khan MA, Qadeer MI. Novel genetic therapeutic approaches for modulating the severity of  $\beta$ -thalassemia (Review). *Biomed Reports*. 2020;13(5):1–11.
10. Xie XM, Liu YN, Li J, Jiang F, Li DZ. A Krüppel-Like Factor 1 Gene Mutation Ameliorates the Severity of  $\beta$ -Thalassemia: A Case Report. *Hemoglobin* [Internet]. 2019;43(2):137–9. Available from: <https://doi.org/10.1080/03630269.2019.1607373>
11. Hamid M, Ershadi Oskouei S, Shariati G, Babaei E, Galehdari H, Saberi A, et al. Mutation screening of the krüppel-like factor 1 gene in individuals with increased fetal hemoglobin referred for hemoglobinopathy investigation in south of Iran. *J Pediatr Hematol Oncol*. 2018;40(3):192–5.
12. Padjadjaran U. DETEKSI DAN ANALISIS MUTASI GEN BCL11A PADA  $\beta$  -THALASSEMIA. 2021;
13. Indonesia U, Rachmaniah D. Fakultas ilmu keperawatan program magister keperawatan universitas indonesia depok, juli 2012. 2012.
14. Sabath DE. Molecular diagnosis of thalassemias and hemoglobinopathies: An ACLPS critical review. *Am J Clin Pathol*. 2017;148(1):6–15.
15. Angastiniotis M, Lobitz S. Thalassemias: An overview. *Int J Neonatal Screen*. 2019;5(1):1–11.
16. Lohani N, Bhargava N, Munshi A, Ramalingam S. Pharmacological and

- molecular approaches for the treatment of  $\beta$ -hemoglobin disorders. *J Cell Physiol.* 2018;233(6):4563–77.
17. Tepakhan W, Kanjanaopas S, Srewaradachpisal K. Association Between Genetic Polymorphisms and Hb F Levels in Heterozygous  $\beta$ -Thalassemia 3.5 kb Deletions. *Hemoglobin* [Internet]. 2020;44(5):338–43. Available from: <https://doi.org/10.1080/03630269.2020.1811117>
  18. Sanctis V De, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. Mediterranean Journal of Hematology and Infectious Diseases  $\beta$ -Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. *Mediterr J Hematol Infectious Dis* [Internet]. 2017;9:1–11. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333734/pdf/mjhid-9-1-e2017018.pdf>
  19. Kumar R, Sagar C, Sharma D, Kishor P.  $\beta$ -Globin genes: Mutation hot-spots in the global thalassemia belt. *Hemoglobin.* 2015;39(1):1–8.
  20. Huang H, Jiang X, Xiao Z, Yu L, Pham Q, Sun J, et al. Red Cabbage Microgreens Lower Circulating Low-Density Lipoprotein (LDL), Liver Cholesterol, and Inflammatory Cytokines in Mice Fed a High-Fat Diet. 2016;(Ldl).
  21. Laghmich A, Alaoui Ismaili FZ, Barakat A, Ghailani Nourouti N, Khattab M, Bennani Mechita M. Alpha-Thalassemia in North Morocco: Prevalence and Molecular Spectrum. *Biomed Res Int.* 2019;2019.
  22. Thein SL. The molecular basis of  $\beta$ -thalassemia. *Cold Spring Harb Perspect Med.* 2013;3(5).
  23. Heydari N, Shariati L, Khanahmad H, Hejazi Z, Shahbazi M, Salehi M. Gamma reactivation using the spongy effect of KLF1-binding site sequence: An approach in gene therapy for beta-thalassemia. *Iran J Basic Med Sci.* 2016;19(10):1063–9.
  24. Maskoen AM, Reniarti L, Sahiratmadja E, Sisca J, Effendi SH. Shine & Lal index as a predictor for early detection of  $\beta$ -thalassemia carriers in a limited resource area in Bandung, Indonesia. 2019;1–6.
  25. Barkley JS, Kendrick KL, Codling K, Muslimatun S, Pachón H. Anaemia prevalence over time in Indonesia: Estimates from the 1997, 2000, and 2008 Indonesia Family Life Surveys. *Asia Pac J Clin Nutr.* 2015;24(3):452–5.
  26. Weatherall DJ. The Evolving Spectrum of the Epidemiology of Thalassemia. *Hematol Oncol Clin North Am.* 2018;32(2):165–75.
  27. Farashi S, Harteveld CL. Molecular basis of  $\alpha$ -thalassemia. *Blood Cells, Mol Dis* [Internet]. 2018;70(April 2017):43–53. Available from: <https://doi.org/10.1016/j.bcmd.2017.09.004>
  28. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN, Weatherall DJ. Global migration and the changing distribution of sickle haemoglobin: A quantitative study of temporal trends between 1960 and 2000. *Lancet Glob Heal.* 2014;2(2).
  29. Adekile A, Sukumaran J, Thomas D, D'Souza T, Haider M. Alpha thalassemia genotypes in Kuwait. *BMC Med Genet.* 2020;21(1):1–5.
  30. Papadopoulos P, Kafasi A, De Cuyper IM, Barroca V, Lewandowski D,

- Kadri Z, et al. Mild dyserythropoiesis and  $\beta$ -like globin gene expression imbalance due to the loss of histone chaperone ASF1B. *Hum Genomics*. 2020;14(1):1–12.
31. Srivorakun H, Fucharoen G, Sanchaisuriya K, Fucharoen S. Diagnosis of common hemoglobinopathies among South East Asian population using capillary isoelectric focusing system. *Int J Lab Hematol*. 2017;39(1):101–11.
  32. Lee YT, De Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER, et al. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. *Blood*. 2013;122(6):1034–41.
  33. Choudhry VP. Thalassemia Minor and Major: Current Management. *Indian J Pediatr*. 2017;84(8):607–11.
  34. Chondrou V, Kolovos P, Sgourou A, Kourakli A, Pavlidaki A, Kastrinou V, et al. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in  $\beta$ -type hemoglobinopathy patients. *Hum Genomics*. 2017;11(1):1–11.
  35. Wahidiyat PA, Sastroasmoro S, Fucharoen S, Setianingsih I, Putriasih SA. Applicability of a clinical scoring criteria for disease severity of  $\beta$ -thalassemia/ hemoglobin E in Indonesia. *Med J Indones*. 2018;27(1):26–32.
  36. Qadah T, Jamal MS. Computational analysis of protein structure changes as a result of nondeletion insertion mutations in human  $\beta$ -globin gene suggests possible cause of  $\beta$ -thalassemia. *Biomed Res Int*. 2019;2019.
  37. Pratama B, Kurniati I, Kedokteran F, Lampung U. Pendekatan Diagnosis Berbasis Molekuler pada Pasien Talasemia The Molecular-Based Diagnostic Approach on Thalassemia Patient. *J Medula*. 2019;9(2):339–45.
  38. Rujito L. Buku Referensi Talasemia: Genetik Dasar dan Penanganan Terkini. 2020.
  39. Fibach E, Rachmilewitz EA. Pathophysiology and treatment of patients with beta-thalassemia - an update. *F1000Research*. 2017;6(0).
  40. Finotti A, Breda L, Lederer CW, Bianchi N, Zuccato C, Kleanthous M, et al. Recent trends in the gene therapy of  $\beta$ -thalassemia. *J Blood Med*. 2015;6:69–85.
  41. Pourfarzad F, von Lindern M, Azarkeivan A, Hou J, Kia SK, Esteghamat F, et al. Hydroxyurea responsiveness in  $\beta$ -thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. *Haematologica*. 2013;98(5):696–704.
  42. Thein SL. Molecular basis of  $\beta$  thalassemia and potential therapeutic targets. *Blood Cells, Mol Dis* [Internet]. 2018;70(May):54–65. Available from: <http://dx.doi.org/10.1016/j.bcmd.2017.06.001>
  43. Ngim CF, Lai NM, Hong JYH, Tan SL, Ramadas A, Muthukumarasamy P, et al. Growth hormone therapy for people with thalassaemia. *Cochrane Database Syst Rev*. 2020;2020(5).
  44. Taghavifar F, Hamid M, Shariati G. Gene expression in blood from an individual with  $\beta$ -thalassemia: An RNA sequence analysis. *Mol Genet*

- Genomic Med. 2019;7(7):1–13.
45. Sari LT, Kes M. Peer-Reviewer. 2019;6.
  46. Viprakasit V, Ekwattanakit S. Clinical Classification, Screening and Diagnosis for Thalassemia. *Hematol Oncol Clin North Am* [Internet]. 2018;32(2):193–211. Available from: <https://doi.org/10.1016/j.hoc.2017.11.006>
  47. Alaithan MA, Azeez SA, Francis Borgio J. A comprehensive review of the prevalence of beta globin gene variations and the co-inheritance of related gene variants in Saudi Arabians with beta-thalassemia. *Saudi Med J*. 2018;39(4):329–35.
  48. Vinjamur DS, Bauer DE, Orkin SH. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. *Br J Haematol*. 2018;180(5):630–43.
  49. Mettananda S, Higgs DR. Molecular Basis and Genetic Modifiers of Thalassemia. *Hematol Oncol Clin North Am* [Internet]. 2018;32(2):177–91. Available from: <https://doi.org/10.1016/j.hoc.2017.11.003>
  50. Cao A, Moi P, Galanello R. Recent advances in  $\beta$ -thalassemias. *Pediatr Rep*. 2011;3(2).
  51. Tamaddoni A, Khabaz Astaneh S, Tabaripour R, Akhavan-Niaki H. Krüppel-Like Factor 1 Gene Mutations in Thalassemia Patients from North Iran: Report of a New Mutation Associated with  $\beta$ -Thalassemia Intermedia. *Hemoglobin* [Internet]. 2019;43(1):12–7. Available from: <https://doi.org/10.1080/03630269.2019.1567528>
  52. Sripichai O, Fucharoen S. Fetal hemoglobin regulation in  $\beta$ -thalassemia: heterogeneity, modifiers and therapeutic approaches. *Expert Rev Hematol* [Internet]. 2016;9(12):1129–37. Available from: <http://dx.doi.org/10.1080/17474086.2016.1255142>
  53. AbdulAzeez S, Al-Muslami AM, Naserullah ZA, Al-Jarrash S, Al-Suliman AM, Al-Madan MS, et al. KLF1 gene and borderline hemoglobin A2 in Saudi population. *Arch Med Sci*. 2018;14(1):230–6.
  54. Lai Y, Zhou L, Yi S, Chen Y, Tang Y, Yi S, et al. The association between four SNPs (rs7482144, rs4671393, rs28384513 and rs4895441) and fetal hemoglobin levels in Chinese Zhuang  $\beta$ -thalassemia intermedia patients. *Blood Cells, Mol Dis* [Internet]. 2017;63:52–7. Available from: <http://dx.doi.org/10.1016/j.bcmd.2017.01.011>
  55. Brancaloneoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. *Int J Lab Hematol*. 2016;38:32–40.
  56. Guy LG, Mei Q, Perkins AC, Orkin SH, Wall L. Erythroid Kruppel-like factor is essential for  $\beta$ -globin gene expression even in absence of gene competition, but is not sufficient to induce the switch from  $\gamma$ -globin to  $\beta$ -globin gene expression. *Blood* [Internet]. 1998;91(7):2259–63. Available from: <http://dx.doi.org/10.1182/blood.V91.7.2259>
  57. Oikonomidou PR, Rivella S. What can we learn from ineffective erythropoiesis in thalassemia? *Blood Rev*. 2018;32(2):130–43.
  58. Wilber A, Hargrove PW, Kim YS, Riberdy JM, Sankaran VG, Papanikolaou E, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of  $\beta$ -

- thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. *Blood*. 2011;117(10):2817–26.
59. Lim M, Brown HM, Kind KL, Thompson JG, Dunning KR. Hemoglobin: Potential roles in the oocyte and early embryo. *Biol Reprod*. 2019;101(2):262–70.
60. Avni R, Golani O, Akselrod-Ballin A, Cohen Y, Biton I, Garbow JR NM. MR Imaging – derived Oxygen- Hemoglobin Dissociation Curves. *Radiology*. 2016;Jul;280((1)):68-77.
61. Siatecka M, Bieker JJ. The multifunctional role of EKLF/KLF1 during erythropoiesis. *Blood*. 2011;118(8):2044–54.
62. Liu D, Zhang X, Yu L, Cai R, Ma X, Zheng C, et al. Erythroid Kruppel-like factor mutations are relatively more common in a thalassemia endemic region and ameliorate the clinical and hematological severity of beta-thalassemia. *Blood*. 2014;124(5):803–12.
63. Mousavi Z, Yazdani Z, Moradabadi A, Hoseinpourkasgari F, Hassanshahi G. Role of some members of chemokine/cytokine network in the pathogenesis of thalassemia and sickle cell hemoglobinopathies: A mini review. *Exp Hematol Oncol* [Internet]. 2019;8(1):4–9. Available from: <https://doi.org/10.1186/s40164-019-0145-x>
64. Hariharan P, Colah R, Ghosh K, Nadkarni A. Differential role of Kruppel like factor 1 (KLF1) gene in red blood cell disorders. *Genomics* [Internet]. 2019;111(6):1771–6. Available from: <https://doi.org/10.1016/j.ygeno.2018.11.032>
65. Fanis P, Kousiappa I, Phylactides M, Kyrri A, Hadjigavriel M, Christou S, et al. A novel mutation in the erythroid transcription factor KLF1 is likely responsible for ameliorating  $\beta$ -thalassemia major. *Hum Mutat* [Internet]. 2019;40(10):1768–80. Available from: <http://dx.doi.org/10.1002/humu.23817>
66. Grech L, Borg J. Control of globin gene expression by Kruppel-like Factors Developmental Control Globin Gene Expression of. *J Malta Chamb Sci*. 2014;(April).
67. Kulczynska-Figurny K, Bieker JJ, Siatecka M. Severe anemia caused by dominant mutations in Krüppel-like factor 1 (KLF1). *Mutat Res - Rev Mutat Res* [Internet]. 2020;786:108336. Available from: <https://doi.org/10.1016/j.mrrev.2020.108336>
68. Ravindranath Y, Johnson RM, Goyette G, Buck S, Gadgeel M, Gallagher PG. KLF1 E325K-associated congenital dyserythropoietic anemia type IV: Insights into the variable clinical severity. *J Pediatr Hematol Oncol*. 2018;40(6):e405–9.
69. Hariharan P, Gorivale M, Colah R, Ghosh K, Nadkarni A. Does the Novel KLF1 Gene Mutation Lead to a Delay in Fetal Hemoglobin Switch? *Ann Hum Genet*. 2017;81(3):125–8.
70. Magor GW, Tallack MR, Gillinder KR, Bell CC, McCallum N, Williams B, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. *Blood*. 2015;125(15):2405–17.
71. Perkins A, Xu X, Higgs DR, Patrinos GP, Arnaud L, Bieker JJ. Kruppeling

- erythropoiesis - an unexpected broad spectrum of. *Blood*. 2016;127(15):1856–63.
72. Wienert B, Martyn GE, Funnell APW, Quinlan KGR, Crossley M. Wake-up Sleepy Gene: Reactivating Fetal Globin for  $\beta$ -Hemoglobinopathies. *Trends Genet* [Internet]. 2018;34(12):927–40. Available from: <https://doi.org/10.1016/j.tig.2018.09.004>
  73. Tepakhan W, Yamsri S, Fucharoen G, Sanchaisuriya K, Fucharoen S. Krüppel-like factor 1 mutations and expression of hemoglobins F and A2 in homozygous hemoglobin E syndrome. *Ann Hematol*. 2015;94(7):1093–8.
  74. Wang Z, Luo G, Ji Y. A novel 519-525dup mutation of KLF1 gene identified in a Chinese blood donor with Lu(a-b-) phenotype. *Transfusion*. 2013;53(7):1619–20.
  75. Khamphikham P, Sripichai O, Munkongdee T, Fucharoen S, Tongsimma S, Smith DR. Genetic variation of Krüppel-like factor 1 (KLF1) and fetal hemoglobin (HbF) levels in  $\beta$ 0-thalassemia/HbE disease. *Int J Hematol*. 2018;107(3):297–310.
  76. Satuti Nur Handayani N, Tripramudya Onggo A. Identifikasi Mutasi Gen  $\beta$  Globin Ekson 1 Pada Pembawa Thalassemia. *Biog J Ilm Biol*. 2014;2(1):63–9.
  77. Shariati L, Khanahmad H, Salehi M, Hejazi Z, Rahimmanesh I, Tabatabaiefar MA, et al. Genetic disruption of the KLF1 gene to overexpress the  $\gamma$ -globin gene using the CRISPR/Cas9 system. *J Gene Med*. 2016;18(10):294–301.
  78. Dame C, Juul SE. The switch from fetal to adult erythropoiesis. *Clin Perinatol*. 2000;27(3):507–26.
  79. Sotianingsih, AS C, M I. Skrining Thalassemia Pada Suku Anak Dalam Di Provinsi Jambi. *Jmj*. 2018;6(2):159–64.
  80. Lim ML. P-Thalassemia. 1989;971–5.
  81. Traivaree C, Boonyawat B, Monsareenusorn C. Molecular analysis of beta-globin gene mutations among Thai beta-thalassemia children: results from a single center study. *Appl Clin Genet*. 2014;253.
  82. Zahratul R, Raja A, Yusoff MM, Xuan D, Koh R, Hussin NH, et al. Molecular Characterisation of  $\alpha$  - and  $\beta$  -Thalassaemia among Indigenous Senoi Orang Asli Communities in Peninsular Malaysia. 2017;1–8.
  83. Abdulazeez S, Sultana S, Almandil NB, Almohazey D, Bency BJ, Borgio JF. The rs61742690 (S783N) single nucleotide polymorphism is a suitable target for disrupting BCL11A-mediated foetal-to-adult globin switching. *PLoS One*. 2019;14(2):1–18.
  84. Pereira C, Relvas L, Bento C, Abade A, Ribeiro ML. POLYMORPHIC VARIATIONS INFLUENCING FETAL HEMOGLOBIN LEVELS: ASSOCIATION STUDY IN BETA-THALASSEMIA CARRIERS AND IN NORMAL INDIVIDUALS OF PORTUGUESE ORIGIN Centre for Anthropology and Health ( CIAS ), Department of Life Sciences , of Hematology , Centro Ho. :1–19.
  85. Kumar R, Yadav R, Mishra S, Singh MPSS, Gwal A, Bharti PK, et al. Krüppel-like factor 1 (KLF1) gene single nucleotide polymorphisms in

- sickle cell disease and its association with disease-related morbidities. *Ann Hematol.* 2021;100(2):365–73.
86. Genc A, Tastemir Korkmaz D, Bayram S, Rencuzogullari E. The Effect of Five Single Nucleotide Polymorphisms on Hb F Variation of  $\beta$ -Thalassemia Traits and Hematologically Normal Individuals in Southeast Turkey. *Hemoglobin* [Internet]. 2020;0(0):231–9. Available from: <https://doi.org/10.1080/03630269.2020.1787178>
  87. Heshusius S, Grech L, Gillemans N, Brouwer RWW, den Dekker XT, van IJcken WFJ, et al. Epigenomic analysis of KLF1 haploinsufficiency in primary human erythroblasts. *Sci Rep* [Internet]. 2022;12(1):1–11. Available from: <https://doi.org/10.1038/s41598-021-04126-6>
  88. Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, et al. A scoring system for the classification of  $\beta$ -thalassemia/Hb E disease severity. *Am J Hematol.* 2008;83(6):482–4.
  89. Srivorakun H, Thawinan W, Fucharoen G, Sanchaisuriya K, Fucharoen S. Thalassemia and erythroid transcription factor KLF1 mutations associated with borderline hemoglobin A2 in the Thai population. *Arch Med Sci.* 2022;18(1):112–20.
  90. Zakaria NA, Islam MA, Abdullah WZ, Bahar R, Yusoff AAM, Wahab RA, et al. Epigenetic insights and potential modifiers as therapeutic targets in  $\beta$ -thalassemia. *Biomolecules.* 2021;11(5).
  91. Jiwu L, Manna S, Lai M, Ying Z, Yanhui L. Hyperhaemolysis in a pregnant woman with a homozygous  $\beta$ 0-thalassemia mutation and two genetic modifiers. *Mol Genet Genomic Med.* 2021;9(7):1–6.
  92. Lou JW, Li DZ, Zhang Y, He Y, Sun MN, Ye WL, et al. Delineation of the molecular basis of borderline hemoglobin A2 in Chinese individuals. *Blood Cells, Mol Dis.* 2014;53(4):261–4.
  93. Mohammadai-Asl J, Ramezani A, Norozi F, Alghasi A, Asnafi AA, Jaseb K, et al. The Influence of Polymorphisms in Disease Severity in  $\beta$ -Thalassemia. *Biochem Genet.* 2015;53(9–10):235–43.
  94. Liu D, Zhang X, Yu L, Cai R, Ma X, Zheng C, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of  $\beta$ -thalassemia. *Blood.* 2014;124(5):803–11.
  95. Mtatiro SN, Mgaya J, Singh T, Mariki H, Rooks H, Soka D, et al. Genetic association of fetal-hemoglobin levels in individuals with sickle cell disease in Tanzania maps to conserved regulatory elements within the MYB core enhancer. *BMC Med Genet.* 2015;16(1):4–11.
  96. Borg J, Patrinos GP, Felice AE, Philipsen S. Erythroid phenotypes associated with KLF1 mutations. *Haematologica.* 2011;96(5):635–8.